Shanghai issues first general technical standard for plant-derived nanovesicles

A Shanghai industry association has released China’s first general technical standard for plant-derived exosome-like nanovesicles, setting baseline purity and concentration requirements for a fast-growing ingredient category used in cosmetics, medical devices and specialized nutrition. The move could make it easier for companies to register, file and commercialize products built on the natural nanomaterial.

Why it matters: - The new standard gives China’s PELNV sector a shared technical baseline for product quality, testing and industrial scale-up. - It sets minimum purity and concentration thresholds that downstream companies can use in registration and filing work. - The standard is aimed at a material with commercial potential across cosmetics, wound care, functional nutrition and pharmaceutical research. - The four application areas covered by the standard sit inside end-markets in China worth more than RMB 2 trillion annually.

What happened: - The Shanghai Yangtze River Delta Medical Device Industry Promotion Association released group standard T/SDMDA 003—2026 on July 20 in Shanghai. - The standard is titled “General Technical Guidelines for the Industrialization of Plant-Derived Exosome-Like Nanovesicles (PELNVs).” - The document takes effect Aug. 1, 2026. - Hangzhou Omni Dynamics Biotechnology Co., Ltd. served as the principal drafting organization. - The association describes the document as the first general technical standard covering PELNV industrialization across the full production chain.

The details: - PELNVs are nanoscale vesicles extracted from plant material. - The vesicles have a lipid bilayer membrane and typically measure 30 to 500 nanometers in diameter. - PELNVs naturally carry proteins, nucleic acids and metabolites. - Researchers have studied the vesicles for their ability to transport bioactive compounds between cells. - The standard sets a minimum purity of 70 percent. - The standard sets a minimum particle concentration of 10^9 particles per milliliter. - The document addresses production, testing and quality-evaluation methods for cosmetics, medical devices, foods for special medical purposes and pharmaceutical development. - Dr. Qian Xueqing, chief executive of Hangzhou Omni Dynamics Biotechnology and the standard’s principal drafter, said quality specifications for a new raw material give downstream companies a common technical language for product registration and filings. - Lin Senyong, president of the Shanghai Yangtze River Delta Medical Device Industry Promotion Association, said the standard is designed to provide consistent terminology and quality-evaluation criteria. - Lin said inconsistent terminology and evaluation criteria had been a barrier to commercial adoption. - Hangzhou Omni Dynamics Biotechnology was established in 2025. - The company’s founding team had worked on plant-derived vesicle technology for about four years before incorporation. - Drafting of the standard took roughly three years. - The company says its development work uses genomics, metabolomics and spatial proteomics platforms. - The company says validation testing was done with research teams at Shanghai Jiao Tong University, Fudan University and Jiangnan University. - Runda Medical Technology Co., Ltd. (SH: 603108) holds a 20 percent equity stake in Hangzhou Omni Dynamics through a subsidiary. - The company says it has established production capacity intended to supply raw material to manufacturers in China and abroad. - Four organizations have committed to implement the standard in its first phase: Shanghai Runda Rongjia Biotechnology Co., Ltd.; Hangzhou Omni Dynamics Biotechnology Co., Ltd.; Shanghai Dongli Health Research Institute Co., Ltd.; and Minuo (Shanghai) Exosome Biomedicine Co., Ltd.

Between the lines: - The standard arrives as Chinese regulators and manufacturers show rising interest in natural ingredients and novel raw materials. - China’s cosmetics market reached RMB 1.07 trillion in transaction value in 2024, while the country’s medical device market exceeded RMB 1.09 trillion that year. - The market for foods for special medical purposes reached RMB 23.2 billion in 2024, up 24 percent year over year. - Within cosmetics, raw materials accounted for roughly RMB 65 billion in China in 2024. - Functional skincare, the segment most directly relevant to PELNVs, was estimated at about RMB 48.7 billion. - The global cosmetic active ingredients segment was valued at about USD 24 billion in 2024. - New cosmetic ingredient filings in China reached 90 in 2024, a record high. - Few companies in China currently produce PELNVs at commercial scale, which makes standard-setting especially important for market entry and scale-up. - Professor Ma Gang of the Bio-X Institute at Shanghai Jiao Tong University said source control and batch-to-batch consistency remain central obstacles to commercial translation. - That challenge is one of the main issues the new standard is intended to address. - At the release event, Professor Liu Yun of the Shanghai Cancer Institute presented research on anti-inflammatory activity, antioxidant effects, gut health and delivery of bioactive compounds.

What's next: - Hangzhou Omni Dynamics and the first-phase adopters are expected to begin using the standard in production and quality systems. - The standard may help companies move PELNV-based raw materials closer to cosmetic filing, medical device development and medical nutrition registration pathways. - No cosmetic, medical device or drug approval was announced with the standard release. - The company says its medical device work has included preliminary discussions with China’s National Medical Products Administration on a Class III drug-device combination pathway, but no regulatory application has been approved. - The company says its foods for special medical purposes work remains subject to registration requirements for medical foods. - The company says its pharmaceutical work is still at the research stage and no drug candidate has entered clinical development. - More information is available in the company’s announcement.

The bottom line: - Shanghai’s new standard turns PELNVs from an emerging research ingredient into a more formalized industrial category, with quality rules that could speed commercialization if products clear the regulatory path.